Peginterferon alfa-2a: all 237 studies that test it
Page 1 of 3. Open to participants first (3), then studies with results posted, then the rest; newest registration first within each.
- A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis BRecruitingNCT07389044Phase 1
- AlloHCT With PegINFa for MyelofibrosisRecruitingNCT05535764Phase 1
- Effect of Low-dose Interferon-alfa2a on Peri-operative Immune SuppressionRecruitingNCT04798612Phase 2
- Study of the Efficacy and Safety of Pegnano Plus Barivir (Ribavirin) in Treatment-naïve Patients With Chronic Hepatitis C at KienGiang General HospitalCompletedNCT06922643Phase 4Results posted
- Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionCompletedNCT04412863Phase 2Results posted
- Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)CompletedNCT03852433Phase 2Results posted
- Role of Pegylated Interferon in Combination With DAAs to Cure Hepatitis C As Soon As Possible - Hepatitis C [ASAP-C]CompletedNCT03480932Phase 2/3Results posted
- Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China IIICompletedNCT03020082Phase 3Results posted
- Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agentCompletedNCT02888106Phase 2Results posted
- A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical StudiesCompletedNCT02829775Phase 2/3Results posted
- HELPS Study - A Study of Peginterferon Alfa-2a (Pegasys) in Patients With Chronic Hepatitis C (CHC) and End-Stage Renal Disease (ESRD)CompletedNCT02806505Phase 3Results posted
- A Study of Peginterferon Alfa-2a in Participants With Chronic Hepatitis B Virus (HBV) in an Expanded Access ProgramCompletedNCT02791269Phase 4Results posted
- Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)CompletedNCT02736721Phase 3Results posted
- A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD)CompletedNCT02732639Phase 3Results posted
- Influence of Ribavirin on the Initial Virological Response in Treatment Naïve Patients With Hepatitis C Genotype 1 InfectionCompletedNCT02716779Phase 2Results posted
- A Study of Peginterferon Alfa-2a (Pegasys) When Administered in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC)CompletedNCT02641379Phase 4Results posted
- Evaluation of Unipeg® for Response and Ongoing Safety in Pakistani PopulationCompletedNCT02601976Phase 4Results posted
- Directly Observed Therapy for HCV in Chennai, IndiaCompletedNCT02541409Phase 2Results posted
- Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral TherapyCompletedNCT02471430Phase 1/2Results posted
- Add-on Peginterferon Following Nucleos(t)Ide Analogue TreatmentCompletedNCT02364336Phase 2Results posted
- Peginterferon Alfa-2a to Enhance Anti-leukemic Responses After Allogeneic Transplantation in Acute Myeloid LeukemiaCompletedNCT02328755Phase 1/2Results posted
- A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant PhaseCompletedNCT02263079Phase 3Results posted
- A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys TrialsCompletedNCT01853254Phase 3Results posted
- An Expanded Access Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Negative Chronic Hepatitis BCompletedNCT01787279Phase 4Results posted
- Pegylated Interferon Alpha-2b in Early Primary MyelofibrosisTerminatedNCT01758588Phase 2Results posted
- Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis CCompletedNCT01753557Phase 3Results posted
- A Study of Pegasys (Peginterferon Alfa-2a) Added to Nucleos(t)Ide Analogue Treatment in Participants With HBeAg-Negative Chronic Hepatitis B Genotype D Showing Stable Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) SuppressionCompletedNCT01706575Phase 2Results posted
- Phase 3 Efficacy and Safety Study of Peginterferon Lambda-1a and Ribavirin With TelaprevirCompletedNCT01598090Phase 3Results posted
- A Study of The Relationship Between Drop in Hemoglobin and Sustained Virological Response in Patients With Chronic Hepatitis C Treated With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a)CompletedNCT01585324Phase 4Results posted
- Safety and Efficacy of Boceprevir/Peginterferon Alfa-2a/Ribavirin in Interleukin-28B CC Allele-Positive Chronic Hepatitis C Virus (HCV) Genotype 1 Participants (P07755)CompletedNCT01544920Phase 3Results posted
- Peg-interferon ADDed to an Ongoing Nucleos(t)Ide Based Treatment in Patients With Chronic Hepatitis B to Induce Decrease of HBs-AntigenCompletedNCT01524679Phase 2Results posted
- A Study of Pegasys (Peginterferon Alfa-2a) Versus Untreated Control in Children With HBeAg Positive Chronic Hepatitis BCompletedNCT01519960Phase 3Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B.CompletedNCT01519921Phase 4Results posted
- Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis CCompletedNCT01498068Phase 3Results posted
- Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV VirusCompletedNCT01471574Phase 3Results posted
- An Open Label Study of the Effect of Telaprevir in Combination With Ribavirin and Peginterferon on HCV Infection in Stable Liver Transplant PatientsTerminatedNCT01467505Phase 2Results posted
- Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis CTerminatedNCT01467492Phase 4Results posted
- A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)TerminatedNCT01467479Phase 3Results posted
- Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC GenotypeTerminatedNCT01459913Phase 3Results posted
- A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)CompletedNCT01447420Phase 4Results posted
- A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)CompletedNCT01429792Phase 4Results posted
- Study of pegInterferon Alfa-2a, Ribavirin, and Daclatasvir (BMS-790052) With or Without BMS-650032 for Participants in Some Hepatitis C Virus TrialsCompletedNCT01428063Phase 2Results posted
- Pegasys in Patients With Chronic Myeloid Leukemia (CML)TerminatedNCT01392170Phase 2Results posted
- BMS-790052 (Daclatasvir) Plus Peg-Interferon Alfa-2a and Ribavirin in Treatment-Naive Black/African-Americans, Latinos and White/Caucasians With Hepatitis CCompletedNCT01389323Phase 3Results posted
- 100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)CompletedNCT01378104Phase 4Results posted
- Combination Therapy of Pegylated Interferon Alfa-2a and Tenofovir Versus Tenofovir Monotherapy in Chronic Hepatitis BCompletedNCT01369212Phase 3Results posted
- A Rollover Study of BI 201335 in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-experienced Genotype 1 Hepatitis C Infected PatientsCompletedNCT01330316Phase 3Results posted
- Efficacy and Safety of BI 201335 (Faldaprevir) in Combination With Pegylated Interferon-alpha and Ribavirin in Treatment-naïve Genotype 1 Hepatitis C Infected Patients (STARTverso 2)CompletedNCT01297270Phase 3Results posted
- A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based TherapyCompletedNCT01288209Phase 3Results posted
- Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)CompletedNCT01259856Phase 3Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a) Plus Ribavirin in Patients With Chronic Hepatitis C (CHC), Genotype 2 or 3CompletedNCT01258101Phase 4Results posted
- VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus InfectionCompletedNCT01241760Phase 3Results posted
- Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve ParticipantsCompletedNCT01215643Phase 2Results posted
- Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous TreatmentCompletedNCT01183169Phase 2Results posted
- A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)CompletedNCT01095835Phase 3Results posted
- VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir PlaceboCompletedNCT01054573Phase 3Results posted
- A Study of Extended Therapy of PEGASYS (Peginterferon Alfa-2a) in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C and Slow ResponseCompletedNCT01033448Phase 4Results posted
- Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected SubjectsCompletedNCT00991289Phase 2Results posted
- Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIVCompletedNCT00983853Phase 2Results posted
- A Study of Early Immunologic Response in Asian Patients With Chronic Hepatitis B, Treated With Pegasys (Peginterferon Alfa-2a (40KD)), Nucleoside Analogues, or BothCompletedNCT00962871Phase 1Results posted
- Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) PatientsCompletedNCT00947349Phase 2Results posted
- A Study of Combination or Sequential Treatment With PEGASYS (Peginterferon Alfa-2a) and Entecavir in Patients With HBeAg Positive Chronic Hepatitis BCompletedNCT00940485Phase 4Results posted
- A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon Alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis BCompletedNCT00927082Phase 4Results posted
- A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis CCompletedNCT00922779Phase 4Results posted
- Intrahepatic HCV RNA and Telaprevir Kinetics in Hepatitis C Virus (HCV)CompletedNCT00892697Phase 2Results posted
- Treatment of Acute Hepatitis C Virus in HIV Co-InfectionCompletedNCT00845676Phase 4Results posted
- A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner ProtocolsCompletedNCT00800735Phase 3Results posted
- A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral ResponseCompletedNCT00758043Phase 3Results posted
- A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do Not Achieve a Rapid Viral ResponseCompletedNCT00623428Phase 3Results posted
- Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 InfectionCompletedNCT00594880Phase 2Results posted
- An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C ParticipantsCompletedNCT00528528Phase 2Results posted
- Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected PatientsCompletedNCT00495131Phase 4Results posted
- Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis CCompletedNCT00491244Phase 4Results posted
- Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose RibavirinCompletedNCT00491179Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis B.CompletedNCT00487747Phase 4Results posted
- The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE)CompletedNCT00483938Phase 3Results posted
- S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis CCompletedNCT00475176Phase 2Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Chronic Hepatitis C and Chronic Renal Failure.CompletedNCT00474955Phase 4Results posted
- SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).CompletedNCT00442572Phase 2Results posted
- A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis BCompletedNCT00436163Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).CompletedNCT00435825Phase 4Results posted
- Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)TerminatedNCT00412750Phase 3Results posted
- A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis CCompletedNCT00394277Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infectionCompletedNCT00353418Phase 4Results posted
- A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 InfectionCompletedNCT00192647Phase 4Results posted
- Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.CompletedNCT00107653Phase 4Results posted
- REPEAT Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Therapy in Combination With COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Who Did Not Respond to Previous PegIntron (Peginterferon Alfa-2b (12KD))/Ribavirin Combination TherapyCompletedNCT00087646Phase 4Results posted
- PHOENIX Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) Administered After Liver Transplantation for Hepatitis C.CompletedNCT00087633Phase 4Results posted
- Peak Study - A Study of Pegasys (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC).CompletedNCT00087607Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Enrolled in a Methadone Maintenance Treatment Program.CompletedNCT00087594Phase 4Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With Ribavirin in Patients With Chronic Hepatitis C (CHC) Previously Treated With PEG-Intron + RibavirinCompletedNCT00087568Phase 4Results posted
- Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected PatientsCompletedNCT00085917Phase 2Results posted
- Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)CompletedNCT00078403Phase 2Results posted
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C Infection (CHC).CompletedNCT00077649Phase 4Results posted
- ACCELERATE Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Combination With COPEGUS (Ribavirin) in Interferon-Naive Patients With Chronic Hepatitis C (CHC) Infection.CompletedNCT00077636Phase 4Results posted
- Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney DiseaseCompletedNCT00028093Phase 4Results posted
- Pegylated Interferon to Treat Chronic Hepatitis DCompletedNCT00023322Phase 2Results posted
- Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard TreatmentCompletedNCT00006164Phase 3Results posted
- VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis BActive, not recruitingNCT06092333Phase 2
- Interferon Alfa Therapy Based on Th17 Profile in Membranous NephropathyTerminatedNCT05941845Phase 2